Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Changing histopathological diagnostics by genome-based tumor classification.

Kloth M, Buettner R.

Genes (Basel). 2014 May 28;5(2):444-59. doi: 10.3390/genes5020444.

2.

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.

Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11. Review.

PMID:
26358176
3.

On the Way to New Horizons: Telemedicine in Oncology.

Schlag PM.

Oncologist. 1997;2(2):III-IV.

PMID:
10388041
4.

Molecular classification of soft tissue sarcomas and its clinical applications.

Jain S, Xu R, Prieto VG, Lee P.

Int J Clin Exp Pathol. 2010 Apr 23;3(4):416-28. Review.

5.

Biomarkers for personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30. Review.

PMID:
25468140
6.

Translating cancer genomes sequencing revolution into surgical oncology practice.

Katsios C, Ziogas DE, Liakakos T, Zoras O, Roukos DH.

J Surg Res. 2012 Apr;173(2):365-9. doi: 10.1016/j.jss.2010.10.038. Epub 2010 Nov 25.

PMID:
21195428
7.

The breast cancer genome--a key for better oncology.

Vollan HK, Caldas C.

BMC Cancer. 2011 Nov 30;11:501. doi: 10.1186/1471-2407-11-501. Review.

8.

Genetic and molecular markers of urothelial premalignancy and malignancy.

Cordon-Cardo C, Cote RJ, Sauter G.

Scand J Urol Nephrol Suppl. 2000;(205):82-93. Review.

PMID:
11144907
9.

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D.

J Thorac Oncol. 2011 Feb;6(2):244-85. doi: 10.1097/JTO.0b013e318206a221. Review.

10.

Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.

Cheng F, Hong H, Yang S, Wei Y.

Brief Bioinform. 2016 Jun 12. pii: bbw051. [Epub ahead of print]

PMID:
27296652
11.

Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach.

Blanco-Calvo M, Concha Á, Figueroa A, Garrido F, Valladares-Ayerbes M.

Int J Mol Sci. 2015 Jun 15;16(6):13610-32. doi: 10.3390/ijms160613610. Review.

12.

[Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].

Pécuchet N, Legras A, Laurent-Puig P, Blons H.

Ann Pathol. 2016 Jan;36(1):80-93. doi: 10.1016/j.annpat.2015.11.012. Epub 2016 Jan 20. French.

PMID:
26803564
13.

Classification of sarcomas using bioinformatics and molecular profiling.

Dang TA, Man TK.

Curr Pharm Biotechnol. 2007 Apr;8(2):83-91. Review.

PMID:
17430156
14.

The new WHO 2016 classification of brain tumors-what neurosurgeons need to know.

Banan R, Hartmann C.

Acta Neurochir (Wien). 2017 Mar;159(3):403-418. doi: 10.1007/s00701-016-3062-3. Epub 2017 Jan 17. Review.

PMID:
28093610
15.

Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer.

Gunn S, Reveles X, Weldon K, Barrera A, Ishaque M, Taylor D, McCaskill C, Kim J, Shah R, Mohammed M, Barry T, Kaiser B, Patnaik A, Tolcher A.

J Ovarian Res. 2013 Jan 4;6(1):2. doi: 10.1186/1757-2215-6-2.

16.

Current and future molecular profiling of cancer by next-generation sequencing.

Shibata T.

Jpn J Clin Oncol. 2015 Oct;45(10):895-9. doi: 10.1093/jjco/hyv122. Epub 2015 Aug 19. Review.

PMID:
26292697
17.

The role of the toxicologic pathologist in the post-genomic era(#).

Maronpot RR.

J Toxicol Pathol. 2013 Jun;26(2):105-10. doi: 10.1293/tox.26.105. Epub 2013 Jul 10.

18.

Nanotechnology: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1.

19.

Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Mariño-Enríquez A, Bovée JV.

Surg Pathol Clin. 2016 Sep;9(3):457-73. doi: 10.1016/j.path.2016.04.009. Review.

PMID:
27523972
20.

Molecular diagnostics in gastric cancer.

Bornschein J, Leja M, Kupcinskas J, Link A, Weaver J, Rugge M, Malfertheiner P.

Front Biosci (Landmark Ed). 2014 Jan 1;19:312-38. Review.

PMID:
24389187

Supplemental Content

Support Center